Website consolidation strategy in pharma: deciding what to merge, keep, and retire

Most pharma companies do not decide from the start to run forty different websites. They arrive at forty websites one launch, one campaign, one acquisition at a time, and then discover that nobody can say what half of them are for.

Key takeaways

Website consolidation is how you get back to a portfolio you can govern. The hard part is the decision: which sites earn their place, which get folded into something bigger, and which should quietly come down.

This guide provides a framework for making those calls while protecting your search visibility.

• Website consolidation is a portfolio decision, not a technical project

Consolidation reduces the number of websites you operate. A migration moves the same sites to a new platform, and a redesign changes how they look. Only site consolidation changes what you own.

• Every site should be scored before it is judged

Traffic, brand equity, audience, maintenance cost, and compliance risk produce a defensible merge, keep, or retire decision.

• Keep a website when it serves a genuinely distinct audience or regulatory obligation

HCP and patient audiences, and markets with separate claim approvals, are the strongest reasons not to merge.

• Multiple domains split your authority rather than multiply it

One brand running two domains competes with itself in search; domain consolidation concentrates that equity into a single property.

1. What is a website consolidation strategy?

A website consolidation strategy is a plan to reduce a fragmented portfolio of brand, country, and campaign websites into a smaller set of governed properties. It defines which sites you merge, which you keep, which you retire, and how you preserve search equity, content value, and regulatory compliance in the process.

If you run digital for a pharma company, you probably inherited more websites than anyone intended to build. A global brand site here, eleven country versions there, a disease-awareness microsite from a 2018 campaign, and a HCP portal on a different platform. Each was a reasonable decision on its own. Together they are a portfolio nobody owns.

The consolidation process is often confused with two adjacent projects, so it is worth separating them. A migration changes the platform. A redesign changes the interface.

Consolidation changes the portfolio itself; you end up with fewer websites than you started with, governed by one operating model. Migration is usually a tactic inside a consolidation, not a synonym for it.

At pharma scale, consolidation typically means bringing brand sites, country sites, disease-area microsites, and HCP portals onto one platform with a shared design system, a single MLR workflow, and clear ownership per market.

The reason global enterprises consolidate websites is rarely the websites themselves. It’s that a fragmented portfolio makes every subsequent decision slower: every launch requires a new build, every claim update must be chased across properties, and every audit surfaces a site nobody can account for.

2. Why pharma web portfolios fragment and what it costs

According to Pharmaphorum, “every product, every therapy area, and often every market had its own website,” and what seemed logical at the time produced “a landscape that is fragmented and difficult to navigate,” leaving digital teams “maintaining large portfolios of platforms, each with their own quirks.”

Four forces drive the growth:

• Launches create a brand site, because a launch budget can fund one.

• Country rollouts multiply that site across markets, each with local claims and a local agency.

• Acquisitions import an entire portfolio overnight, on platforms you did not choose.

• Agency handoffs leave properties whose passwords, hosting, and analytics belong to a partner you no longer work with.

And the cost shows up in three places:

• Search

Running multiple websites for one company splits the authority that should be concentrated in one place. Two properties covering the same therapy area compete for the same keywords, duplicate content forces search engines to pick a canonical you did not choose, and inbound links scatter across domains instead of compounding into a single one. You are bidding against yourself.

• Operations

Every additional platform is another content model, release process, or MLR workflow. A claim change that should take one update takes eleven, and each of the eleven needs its own review.

• Compliance

This is the cost that matters most in pharma and gets discussed least. An unmaintained campaign microsite still carries approved claims, still displays safety information, and still ranks. If nobody owns it, nobody is updating it when the label changes.

3. When to consolidate: the triggers

Most consolidation processes begin when something forces the question. Three triggers account for the majority of them:

• Mergers, acquisitions, and divestments

An acquisition hands you a second portfolio with its own domains, platforms, and rankings, often including a site that outranks yours for terms you care about. A divestment creates the opposite problem: content has to leave your estate without taking your search visibility with it.

Both need a deliberate domain and redirect strategy, decided before the deal closes rather than discovered afterward. The common failure is letting the acquired domain sit untouched for years, by which point its authority has decayed, and the redirect is worth a fraction of what it would have been.

• Brand portfolio rationalization

When the product portfolio is pruned, the web estate rarely is. Sites for discontinued or delisted products linger, and their digital footprint no longer matches their commercial one.

• Platform end-of-life or CMS standardization

When a platform loses support, or IT mandates a single stack, you are rebuilding anyway. That is the cheapest moment to reduce the number of sites, because the migration cost is already committed.

How to know when to merge websites

You likely have a consolidation problem, rather than a maintenance one, if you can answer yes to three or more of these questions:

• You cannot produce a current, complete list of all the sites your company owns.

• Two or more properties target the same audience and the same therapy area.

• A site has had no content update, and no identifiable owner, for over 12 months.

• The same claim or safety information exists in more than three places.

• A new market launch requires a new build rather than a new instance.

• You are paying for hosting or licenses on properties nobody can attribute to a budget.

4. The M/K/R framework: deciding what to merge, keep, and retire

The M/K/R framework sorts every property in your portfolio into one of three outcomes (merge, keep, or retire) by scoring it against five dimensions before any decision is made.

Its purpose is to move the conversation from opinion to evidence, because the hardest part of content consolidation is telling a brand team their site is going away.

Score each website on:

• Traffic and quality of traffic

Not just volume. Rather, see if it reaches the audience you want. A site with 400 monthly HCP visits can matter more than one with 4000 unqualified ones.

• Brand equity

Does the audience know and search for this property by name? Branded search volume is the honest test, not internal attachment.

• Audience distinctness

Does it serve an audience the target site genuinely cannot, such as HCPs vs. patients?

• Maintenance cost

Hosting, licenses, agency retainers, and internal hours nobody counts.

• Compliance risk

How exposed are you if this site isn't updated on the day a label changes?

Sites that score high on brand equity and audience distinctiveness earn their independence. Sites that score high on maintenance costs and compliance risk, but low on traffic, are candidates for retirement. Everything in between merges.

How to merge two websites into one

Once a site is marked for merging, the execution is the same four steps every time:

• Audit both sites

Every page: its traffic, rankings, backlinks, and MLR approval status. You can’t map what you haven’t inventoried.

• Map every old URL to a destination

Each page gets a specific equivalent on the target site, not a lazy redirect to the homepage. Where two pages cover the same ground, decide now which survives and fold the unique value of the other two into it.

• Redirect, then verify

Implement 301s from every retired URL to its mapped destination, and confirm each one resolves in a single hop.

• Monitor for two quarters

Rankings and traffic typically dip before they recover. Watch crawl errors, index coverage, and position for your priority teams, and keep the redirects in place permanently.

5. Microsite strategy: the hardest call in the portfolio

Microsites are where consolidation programs stall, because they are the properties with the most emotional ownership and the least documentation. A sound microsite strategy gives each one of three fates: fold it into the core site as a content section, keep it as a governed satellite on the shared platform, or sunset entirely,

A microsite earns its own URL when it serves a campaign with a defined end date, a non-promotional audience that must stay separate from branded content, or a co-promotion partner whose branding cannot sit on your domain.

If you are facing 100 or more microsites, resist the big-bang rewrite. Sequence the work instead: retire the unowned properties first, since they need no rebuild and immediately reduce compliance exposure.

Then fold the low-traffic survivors into the core site as sections. Then rebuild the genuinely distinct ones as template instances on the shared platform. Most portfolios shrink by half before anyone writes new code, which funds the rest of the program and proves the model works.

6. Domain strategy: where the SEO risk lives

Deciding what to merge is a portfolio question. Deciding where the merged content lives is a domain question, and it is the one that determines whether you keep your search visibility or donate it.

For most pharma portfolios, subfolders on one domain are the strongest default, because every new section inherits the authority the domain has already earned rather than starting from nothing. The exception is the deliberate one: where a gated HCP environment, a partner-branded property, or a regulatory boundary makes separation the point.

One brand, two domains, half the authority

The most common avoidable problem in a fragmented portfolio is having multiple sites serving the same audience. Every inbound link, mention, and ranking signal that should compound into a single property is split.

Domain consolidation fixes this by concentrating those signals into a single property. Domain unification is the brand-side counterpart: a single recognizable address that the audience learns, rather than a set of campaign domains nobody remembers.